Pharmacists in Lab

2025 Health Care Outlook: Susan Cantrell, AMCP

With President Trump and his administration returning to Washington, D.C., and a new Congress set to take shape, there’s naturally some uncertainty when it comes to the future of American health care policy. Looking ahead to 2025, however, there will likely be some key decisions affecting and defining how managed care pharmacy and the larger health care system operate and serve patients.
CMS Letter

AMCP Letter on the Medicare and Medicaid Programs for Contract Year 2026

AMCP shared comments with Centers for Medicare & Medicaid Services (CMS) on the proposed 2026 Policy and Technical Changes to the Medicare Advantage (MA) Program. We applaud CMS’ efforts to address obesity and emphasized the importance of managing costs. AMCP urged CMS to issue guidance on managing drugs in this class to effectively treat obesity as a chronic disease. On the Medicare Transaction Facilitator, we advised CMS to avoid adding unnecessary costs and administrative burdens. We support CMS’ focus on increasing access to generics, biosimilars, and other affordable medications. Lastly, we provided insights on proposed changes to Star Ratings, ensuring member perspectives are represented.
Legislation & Regulation